<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167673</url>
  </required_header>
  <id_info>
    <org_study_id>bp004</org_study_id>
    <nct_id>NCT01167673</nct_id>
  </id_info>
  <brief_title>The Effect of Coltect (Selenium, Curcumin and Green Tea) on Irritable Bowel Syndrome</brief_title>
  <official_title>A Double Blind Placebo Controlled Cross Over Study for the Use of Coltect (Green Tea, Selenium and Curcumin) in Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NAFTALI TIMNA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irritable bowel syndrome (IBS) causes many symptoms, including abdominal pain, irregular
      bowel movements and bloating. It may be caused by loe degree inflammation of the intestine.
      The ingredients of coltect which contains green tea, selenium, and curcumin have been proven
      very safe and have anti inflammatory and anti oxidant activity. The aim of the study is to
      see whether the use of Coltect can improve symptoms in IBS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The etiology of Irritable bowel syndrome is unknown but some evidence suggests it may be
      caused by a certain degree of inflammation, another theory is that intestinal flora has an
      influence on IBS. Coltect combines 3 ingredients: green tea, selenium and curcumin, all of
      which have been shown to have anti inflammatory and anti oxidant activity. the aim of the
      study is to investigate if use of coltect can improve symptoms in IBS patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of IBS symptoms and quality of life</measure>
    <time_frame>10 weeks</time_frame>
    <description>improvement of IBS symptoms and quality of life (QOL) assessed by IBS and QOL questionaires.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in bacterial stool flora</measure>
    <time_frame>10 weeks</time_frame>
    <description>stool tests to investigate change in intestinal flora during the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>treatment with study drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receiving study drug for 4 weeks. 3 capsules a day of coltect</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receiving similar capsules but no active ingredients</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>coltect</intervention_name>
    <description>green tea 250 mg, selenium 100 micro gram, curcumin 500 mg</description>
    <arm_group_label>treatment with study drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IBS as defined by the Rome III criteria

          -  for those above age 40 a colonoscopy within the last 5 years

          -  no new treatment in the last 2 weeks

          -  not receiving any antibiotics in the last 2 weeks

        Exclusion Criteria:

          -  any large abdominal operation (such as colectomy) in the past

          -  a known disease of the gastrointestinal tract

          -  any significant debilitating disease such as sever heart failure, un controlled
             diabetes,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timna Naftali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AYA Oren, MD</last_name>
    <phone>972-9-7471017</phone>
    <email>aya.oren@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastroenterology institute Meir Hospital</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>aya oren, Mrs</last_name>
      <phone>972-9-7471017</phone>
      <email>aya.oren@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Timna Naftali, MD</last_name>
      <phone>972-9-7472580</phone>
      <email>timna.naftali@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Timna Naftali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <last_update_submitted>June 13, 2016</last_update_submitted>
  <last_update_submitted_qc>June 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Meir Medical Center</investigator_affiliation>
    <investigator_full_name>NAFTALI TIMNA</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>irritable bowel syndrome</keyword>
  <keyword>selenium</keyword>
  <keyword>curcumin</keyword>
  <keyword>green tea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

